RxDoctor Payments DataLook up a doctor →

Daniel Uderitz, MD

Psychiatry · Johns Island, SCNPI 1295963437

Payments from drug & device makers

$21,959in general payments, 2019–2025

Across 1,338 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Otsuka America Pharmaceutical, Inc.$3K
  • Lundbeck LLC$2K
  • Sunovion Pharmaceuticals Inc.$2K
  • Supernus Pharmaceuticals, Inc.$1K
  • Axsome Therapeutics, Inc.$1K
  • plus $10K from 31 others

What the payments were for

  • Food & beverage$21,913100%
  • Education$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,959 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$63,826
Medicare patients
85
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$163,385
CaplytaLumateperone Tosylate46$90,431
FanaptIloperidone13$74,059
VraylarCariprazine Hcl23$50,205
RexultiBrexpiprazole18$27,993
Lurasidone Hcl42$17,205
AdderallDextroamphetamine/Amphetamine14$8,534
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine142$3,866
Quetiapine Fumarate108$3,784
Haloperidol Decanoate76$3,429
Aripiprazole82$3,293
Bupropion XlBupropion Hcl99$3,263
Clozapine27$2,902
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine58$2,308
Trazodone Hcl142$1,999

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$930$163,38511 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,152$90,43146 claims
Vanda Pharmaceuticals Inc.Fanapt$1,178$74,05913 claims
AbbVieVraylar$2,840$50,20523 claims
Otsuka America Pharmaceutical, Inc.Rexulti$2,580$27,99318 claims
Takeda Pharmaceuticals U.S.A., Inc.Adderall$1,055$8,53414 claims
Almatica Pharma LLCSertraline Hcl$219$92670 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Johns Island

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →